January 1, 1995Thrombosis and Haemostasis
Advances in Antithrombotic Therapy: Novel Agents
Population
Patients with coronary artery disease and high-risk surgical patients
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Highlights safety concerns with hirudin plus thrombolytics; leaves open the role of direct thrombin inhibitors in unstable angina.
Key Points
- To review the clinical efficacy, therapeutic potential, and safety profiles of direct thrombin inhibitors, particularly recombinant hirudin, across coronary artery disease and venous thromboembolism.
- Reviewed clinical evaluation data examining direct thrombin inhibitors in acute coronary syndromes, including acute myocardial infarction, unstable angina, and non-Q-wave infarction.
- Assessed bleeding risks and safety margins associated with recombinant hirudin combined with aspirin and thrombolytic agents, as well as efficacy in post-surgical deep vein thrombosis.
- Recombinant hirudin demonstrates a narrower safety window than previously anticipated, characterized by increased bleeding concerns when co-administered with aspirin and thrombolytic drugs during acute myocardial infarction.
- Direct thrombin inhibitors provide substantial therapeutic benefit in the initial treatment of acute unstable angina, non-Q-wave infarction, and the prevention of deep vein thrombosis in high-risk surgical settings.
Structured PICO
P
Population
Patients with coronary artery disease (acute myocardial infarction, unstable angina, non-Q-wave infarction) and high-risk surgical patients
I
Intervention
Direct thrombin inhibitors (e.g., recombinant hirudin)
Direct thrombin inhibitors like recombinant hirudin show promise for acute coronary ischemia but require careful dose-finding due to safety concerns when combined with other antithrombotics.
Cite This Study
Turpie et al. (1995) studied this question.